2022 UCSF-Stanford CERSI Immersion Course in Drug Discovery, Development, and Regulation

Friday, September 16, 2022 - 10:00 am to Friday, December 2, 2022 - 1:00 pm
Virtual Event - Times Shown in Pacific Time


The UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) is pleased to announce the 2022 Immersion Course in Drug Discovery, Drug Development, and Regulation. Participants will have the opportunity to learn the scientific and regulatory aspects of drug discovery and development from leading scientists and experts in the biotechnology/pharmaceutical industries and academia. Different therapeutic modalities will be covered, including small molecules, biologics, and gene therapies. 

This is a virtual course comprised of eleven 3-hour sessions held on Fridays from September 16, 2022 through December 2, 2022 from 10 am - 1 pm Pacific Time. Session may include pre-reading assignments, lectures, and discussion of case studies. Participants who successfully complete the course will be issued a Statement of Completion from the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI). Sessions will be recorded and available to all participants for the duration of the course.

Learning objectives

  • Discuss the current regulatory system and structure relevant to drug development and describe two key FDA submissions: the Investigational New Drug (IND) Application and New Drug Application (NDA) / Biologics License Application (BLA)
  • Discuss contemporary approaches to drug discovery, including target identification and computational methods used to design drugs
  • Explain the role of toxicology, pathology, and drug metabolism and pharmacokinetics in the selection and evaluation of drug candidates for clinical testing
  • Describe CMC and quality considerations in the manufacture of drugs and biologics to support all phases of development
  • Explain the different types and applications of biomarkers in clinical drug development
  • Describe the current state and future directions of applications of real-world data (RWD) and real-world evidence (RWE) to drug development
  • Explain the principles of first-in-human studies and starting dose determinations (Phase 1 studies)
  • Describe study design and regulatory considerations for proof-of-concept (Phase 2) and pivotal (Phase 3) clinical studies
  • Discuss key factors for regulatory decision-making, such as benefit-risk assessments
  • Explain the fundamentals of a portfolio strategy and corporate development
  • Discuss emerging and evolving topics such as immuno-oncology and gene therapies

Target audience

  • Early- to mid- career industry scientists and regulatory professionals who would like a broad overview of the latest developments in the field
  • Faculty members interested in understanding drug development to advance discoveries into products
  • Trainees who would like to complement their training and research in basic and applied sciences with a course on the nuts-and-bolts of drug discovery and development


The registration fees for this course are shown below. A group registration discount is available when registering 10 or more people at the same time. Please contact [email protected] for more information.

Registration Category Registration Fee
General Admission / Industry $2,990
Early Bird (Before 8/1/2022) $2,500
Academic / Government* $1,000
Academic Trainees (students/residents/fellows)* $250

*To register under the academic/government or trainee rate, you must sign up using an email address ending in .edu/.gov/.mil.


Course Schedule


Date Topic(s) Instructors


September 9, 2022

Welcome and Networking

This will take place in-person at the UCSF Mission Bay campus from 3:30 pm to 5 pm PT.

Mark Dresser, PhD (SVP, Biomarker Sciences and Clinical Pharmacology, Gilead Sciences)
Dolo Diaz, PhD (SVP, Development Sciences, Denali Therapeutics)


September 16, 2022


Overview of Medical Product Development and Regulation

Mark Dresser, PhD (SVP, Biomarker Sciences and Clinical Pharmacology, Gilead Sciences)
Richard Graham, PhD (SVP, Development, Theravance Biopharma)
Aine Miller, PhD (VP, Head of Regulatory Affairs and Medical Writing, Theravance Biopharma)
Terrell Baptiste, MBA (Associate Director, Regulatory Policy and Intelligence, Gilead Sciences)


September 23, 2022

Drug Discovery (e.g., Target Identification, Small Molecule and Protein-based Therapeutics Discovery)

JW Feng, PhD (Staff Research Scientist, Google Research, Google)
James Crawford, PhD (Senior Principal Scientist, Genentech)


September 30, 2022

Translational Preclinical Evaluations (DMPK, Toxicology, Risk Assessment)

Dolo Diaz, PhD (SVP, Development Sciences, Denali Therapeutics)
Rebecca Erickson, PhD (Senior Director, Toxicology, DiCE Molecules)


October 7, 2022

Chemistry, Manufacturing, and Controls of Drugs and Biologics

Roshy Pakdaman, PhD (VP, Formulation & Process Development, Gilead)
Gayle Derfus, PhD (Executive Director, Drug Substance Process Development, Gilead Sciences)


October 14, 2022

Clinical Biomarkers and Companion Diagnostics: Development and Regulation

Heleen Scheerens, PhD (Senior Director, Global Head of OMNI-Biomarker Development at Genentech)
Rhea Nersesian (Senior Companion Dx Project Leader at Genentech)


October 21, 2022

Applications of Real World Data and Real World Evidence to Drug Discovery and Development

Frank Sifakis, PhD, MPH, MBA (Vice President, Real-World Evidence at Gilead)
Kim Van Naarden Braun, PhD (Senior Scientific Director, Translational Epidemiology at Bristol Myers Squibb)


October 28, 2022

First-in-Human and Clinical Proof-of-Concept Studies (Phase 1 and Phase 2)

Nag Budha, PhD (Clinical Pharmacologist, BeiGene)
Mika Derynck, MD (Chief Medical Officer, Amunix Pharmaceuticals)


November 4, 2022

Pivotal Clinical Trials: Study Design and Regulatory Considerations

Mika Derynck, MD (Chief Medical Officer, Amunix Pharmaceuticals)
Cornelia Irl, PhD (Vice President, Global Head Data & Statistical Sciences – Oncology, Genentech)


November 10, 2022
(NOTE: Thursday)

Medical Product Regulation and Decision Making: Overview, Benefit-Risk Assessments, Case Studies

Issam Zineh, PharmD, MPH (Director, Office of Clinical Pharmacology, FDA)
Henrietta Abodakpi PharmD, PhD (Clinical Pharmacology Reviewer/OCP, FDA)
Rajanikanth Madabushi, PhD (Associate Director, Guidance and Scientific Policy/OCP, FDA)
David Strauss, MD, PhD (Director, Division of Applied Regulatory Science, FDA)
Robert Schuck, PharmD, PhD (Deputy Director, Division of Translational and Precision Medicine/OCP, FDA)


November 18, 2022

Portfolio Strategy and Corporate Development

Andrew McKee, MD (Founder, CEO, and President, Headland Strategy Group)
Ken Shimokawa, PhD (Senior Engagement Manager, Headland Strategy Group)


December 2, 2022

Discovery and Development of Immuno-Oncology Therapies and Gene Therapies

Course Wrap Up

Akintunde (Tunde) Bello, PhD (VP, Clinical Pharmacology and Pharmacometrics at Bristol-Myers Squibb)
Justine Cunningham, PhD, DABT (VP, Toxicology & Biodistribution, Sana Biotechnology, Inc.)
Mark Dresser, PhD (SVP, Biomarker Sciences and Clinical Pharmacology, Gilead Sciences)


December 9, 2022

Career Panel Discussion TBD


Mark Dresser, PhD
Course Co-Director

Senior Vice President, Biomarker Sciences & Clinical Pharmacology, Gilead Sciences
Adjunct Professor of Bioengineering and Therapeutic Sciences, UCSF

Dolo Diaz, PhD
Course Co-Director

Senior Vice President, Development Sciences, Denali Therapeutics

Lawrence Lin, PhD
Course Administrator

Executive Director, UCSF-Stanford CERSI

Nathan Dang, PharmD
Course Coordinator

Program Coordinator, UCSF-Stanford CERSI

Please email [email protected] with any questions.